Evidence map›Paper›PMID 40974429›Full record

ArticleJournal of molecular medicine (Berlin, Germany)2025

Unproductive alternative splicing of ATM exon 7: mapping of critical regulatory elements and identification of 34 spliceogenic variants.

Inés Llinares-Burguet, Lara Sanoguera-Miralles, Alicia García-Álvarez, Ada Esteban-Sánchez, María José Caloca, Miguel de la Hoya, Elena Bueno-Martínez, Eladio A Velasco-Sampedro

Abstract read
In one paragraph

Article in Journal of molecular medicine (Berlin, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Inés Llinares-BurguetSplicing and Genetic Susceptibility to Cancer, Unidad de Excelencia Instituto de Biomedicina y Genética Molecular de Valladolid (IBGM), Universidad de Valladolid - Consejo Superior de Investigaciones Científicas (UVa-CSIC), Sanz y Forés 3, 47003, Valladolid, Spain.ORCID 0000-0002-7838-0838
Lara Sanoguera-MirallesSplicing and Genetic Susceptibility to Cancer, Unidad de Excelencia Instituto de Biomedicina y Genética Molecular de Valladolid (IBGM), Universidad de Valladolid - Consejo Superior de Investigaciones Científicas (UVa-CSIC), Sanz y Forés 3, 47003, Valladolid, Spain.ORCID 0000-0002-5548-7114
Alicia García-ÁlvarezSplicing and Genetic Susceptibility to Cancer, Unidad de Excelencia Instituto de Biomedicina y Genética Molecular de Valladolid (IBGM), Universidad de Valladolid - Consejo Superior de Investigaciones Científicas (UVa-CSIC), Sanz y Forés 3, 47003, Valladolid, Spain.
Ada Esteban-SánchezMolecular Oncology Laboratory, Hospital Clínico San Carlos, IdISSC (Instituto de Investigación Sanitaria del Hospital Clínico San Carlos), Madrid, Spain.
María José CalocaRho GTPasas y Señalización Por Lípidos, Unidad de Excelencia Instituto de Biomedicina y Genética Molecular de Valladolid (IBGM), Universidad de Valladolid - Consejo Superior de Investigaciones Científicas (UVa-CSIC), Valladolid, Spain.ORCID 0000-0002-1003-2685
Miguel de la HoyaMolecular Oncology Laboratory, Hospital Clínico San Carlos, IdISSC (Instituto de Investigación Sanitaria del Hospital Clínico San Carlos), Madrid, Spain.ORCID 0000-0002-8113-1410
Elena Bueno-MartínezSplicing and Genetic Susceptibility to Cancer, Unidad de Excelencia Instituto de Biomedicina y Genética Molecular de Valladolid (IBGM), Universidad de Valladolid - Consejo Superior de Investigaciones Científicas (UVa-CSIC), Sanz y Forés 3, 47003, Valladolid, Spain.ORCID 0000-0003-4888-2885
Eladio A Velasco-SampedroSplicing and Genetic Susceptibility to Cancer, Unidad de Excelencia Instituto de Biomedicina y Genética Molecular de Valladolid (IBGM), Universidad de Valladolid - Consejo Superior de Investigaciones Científicas (UVa-CSIC), Sanz y Forés 3, 47003, Valladolid, Spain. eavelsam@uva.es.ORCID 0000-0002-9682-5589

Funding

Instituto de Salud Carlos III PI20/00225Instituto de Salud Carlos III PI23/00047Instituto de Salud Carlos III PI24/00267
6 · The paper itself

Abstract

ATM loss-of-function variants are significantly associated with increased breast cancer risk. ATM exon 7 skipping (△(E7)) is a naturally-occurring alternative splicing event, which introduces a premature termination codon and represents a form of gene-expression regulation via unproductive splicing. Disruption of splicing regulatory elements (SRE) by variants can lead to mis-splicing, potentially contributing to disease susceptibility. To study the regulatory mechanisms of △(E7) and the impact of exonic variants on splicing, a combined in silico/minigene approach was employed, using the construct mgATM_4-9 (exons 4-9) that recapitulates this splicing event. HEXplorer analysis of ATM exon 7 predicted two splicing enhancer-rich regions (c.665-681 and c.867-898). Deletions of these intervals in mgATM_4-9 significantly increased △(E7) (57-96%), revealing their critical role for exon 7 inclusion. Forty-eight candidate variants (HEXplorer, △HZEI score < -40) within these SRE-rich segments were functionally assayed, 34 of which (71%) impaired exon 7 recognition. Nineteen variants presented strong impacts with high expression of △(E7)-transcripts (69-96%), of which c.668A > T, c.680C > A and c.680C > T exhibited particularly strong effects (4-13% full-length transcripts). DeepCLIP analysis suggested that SR proteins SRSF7 and SRSF10 play a positive regulatory role in exon 7 inclusion. Eight variants were classified as likely pathogenic according to ACMG/AMP-based guidelines. Furthermore, nine missense and two synonymous variants with strong impacts (16-29% full-length transcripts) might represent intermediate risk alleles. This work collectively demonstrates the intricate nature of ATM exon 7 recognition, regulated by cis-acting SREs, emphasizing the value of in silico predictions for initial variant filtering and minigene assays for dissecting splicing regulation and clinical interpretation of variants. KEY MESSAGES: Frameshift ATM exon 7 skipping is an unproductive alternative splicing event that may represent a form of gene-expression regulation. Two SRE-rich intervals are involved in exon 7 recognition. Thirty-four out of 48 tested variants located at these intervals disrupted exon 7 inclusion. Nineteen variants showed strong impacts on splicing. All variant types can impair splicing: 23 missense, 7 nonsense, and 4 synonymous variants upregulate exon 7 skipping. Eight variants were classified as likely pathogenic.

Indexed as

Alternative SplicingAtaxia Telangiectasia Mutated ProteinsExonsRegulatory Sequences, Nucleic AcidFemaleHumansAtaxia Telangiectasia Mutated ProteinsATM protein, humanAberrant splicingATMHereditary breast cancerMinigenesSplicing regulatory elementsUnproductive splicingVariants of uncertain significance

Identifiers

PMID40974429
PMCPMC12675606

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.